LIN vs. NVO: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at LIN and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
LIN is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | LIN | NVO |
|---|---|---|
| Company Name | Linde plc | Novo Nordisk A/S |
| Country | United Kingdom | Denmark |
| GICS Sector | Materials | Health Care |
| GICS Industry | Chemicals | Pharmaceuticals |
| Market Capitalization | 224.07 billion USD | 244.20 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 17, 1992 | April 30, 1981 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of LIN and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LIN | NVO |
|---|---|---|
| 5-Day Price Return | -0.43% | 4.72% |
| 13-Week Price Return | 4.11% | -17.05% |
| 26-Week Price Return | 3.42% | -37.87% |
| 52-Week Price Return | 3.50% | -60.23% |
| Month-to-Date Return | 3.82% | 15.71% |
| Year-to-Date Return | 14.14% | -41.70% |
| 10-Day Avg. Volume | 1.47M | 6.68M |
| 3-Month Avg. Volume | 1.73M | 6.63M |
| 3-Month Volatility | 12.80% | 65.20% |
| Beta | 0.96 | 1.52 |
Profitability
Return on Equity (TTM)
LIN
17.46%
Chemicals Industry
- Max
- 26.17%
- Q3
- 13.48%
- Median
- 8.13%
- Q1
- 2.52%
- Min
- -11.86%
In the upper quartile for the Chemicals industry, LIN’s Return on Equity of 17.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
NVO
77.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
LIN
20.20%
Chemicals Industry
- Max
- 21.80%
- Q3
- 9.57%
- Median
- 4.44%
- Q1
- 1.14%
- Min
- -11.30%
A Net Profit Margin of 20.20% places LIN in the upper quartile for the Chemicals industry, signifying strong profitability and more effective cost management than most of its peers.
NVO
35.61%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
LIN
26.75%
Chemicals Industry
- Max
- 27.33%
- Q3
- 13.97%
- Median
- 8.08%
- Q1
- 4.46%
- Min
- -8.10%
An Operating Profit Margin of 26.75% places LIN in the upper quartile for the Chemicals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
NVO
45.78%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | LIN | NVO |
|---|---|---|
| Return on Equity (TTM) | 17.46% | 77.86% |
| Return on Assets (TTM) | 8.10% | 24.22% |
| Net Profit Margin (TTM) | 20.20% | 35.61% |
| Operating Profit Margin (TTM) | 26.75% | 45.78% |
| Gross Profit Margin (TTM) | 48.45% | 83.95% |
Financial Strength
Current Ratio (MRQ)
LIN
0.93
Chemicals Industry
- Max
- 3.38
- Q3
- 2.23
- Median
- 1.73
- Q1
- 1.39
- Min
- 0.55
LIN’s Current Ratio of 0.93 falls into the lower quartile for the Chemicals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
NVO
0.78
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
LIN
0.67
Chemicals Industry
- Max
- 1.65
- Q3
- 0.94
- Median
- 0.65
- Q1
- 0.41
- Min
- 0.00
LIN’s Debt-to-Equity Ratio of 0.67 is typical for the Chemicals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
NVO
0.59
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
LIN
33.09
Chemicals Industry
- Max
- 56.43
- Q3
- 26.33
- Median
- 9.38
- Q1
- 3.10
- Min
- -9.39
LIN’s Interest Coverage Ratio of 33.09 is in the upper quartile for the Chemicals industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | LIN | NVO |
|---|---|---|
| Current Ratio (MRQ) | 0.93 | 0.78 |
| Quick Ratio (MRQ) | 0.70 | 0.56 |
| Debt-to-Equity Ratio (MRQ) | 0.67 | 0.59 |
| Interest Coverage Ratio (TTM) | 33.09 | 149.07 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
LIN
1.21%
Chemicals Industry
- Max
- 6.56%
- Q3
- 4.04%
- Median
- 2.47%
- Q1
- 1.45%
- Min
- 0.00%
LIN’s Dividend Yield of 1.21% is in the lower quartile for the Chemicals industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
NVO
3.30%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
LIN
40.71%
Chemicals Industry
- Max
- 181.25%
- Q3
- 95.01%
- Median
- 53.52%
- Q1
- 26.59%
- Min
- 0.00%
LIN’s Dividend Payout Ratio of 40.71% is within the typical range for the Chemicals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
NVO
61.60%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | LIN | NVO |
|---|---|---|
| Dividend Yield (TTM) | 1.21% | 3.30% |
| Dividend Payout Ratio (TTM) | 40.71% | 61.60% |
Valuation
Price-to-Earnings Ratio (TTM)
LIN
33.69
Chemicals Industry
- Max
- 42.94
- Q3
- 29.77
- Median
- 20.37
- Q1
- 14.27
- Min
- 6.19
A P/E Ratio of 33.69 places LIN in the upper quartile for the Chemicals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
NVO
13.91
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
LIN
6.80
Chemicals Industry
- Max
- 4.36
- Q3
- 2.23
- Median
- 1.01
- Q1
- 0.55
- Min
- 0.16
With a P/S Ratio of 6.80, LIN trades at a valuation that eclipses even the highest in the Chemicals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
NVO
4.95
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
LIN
5.73
Chemicals Industry
- Max
- 4.92
- Q3
- 2.56
- Median
- 1.54
- Q1
- 0.97
- Min
- 0.30
At 5.73, LIN’s P/B Ratio is at an extreme premium to the Chemicals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
NVO
8.87
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | LIN | NVO |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 33.69 | 13.91 |
| Price-to-Sales Ratio (TTM) | 6.80 | 4.95 |
| Price-to-Book Ratio (MRQ) | 5.73 | 8.87 |
| Price-to-Free Cash Flow Ratio (TTM) | 44.62 | 23.46 |